公司近况5 月30 日,公司合作伙伴summit公布AK112 联合化疗用于2L EGFRmNSCLC的全球多中心III期临床HARMONi研究结果,PFS HR=0.52,OSHR=0.79,显示成功达到PFS主要终点,OS具有明显获益趋势。评论国际多中心临床HARMONi和中国临床HARMONi-A结果具备一致性。据康方和summit公告,HARMONi临床计划入组420 人,其中38%为欧美...
Source Link公司近况5 月30 日,公司合作伙伴summit公布AK112 联合化疗用于2L EGFRmNSCLC的全球多中心III期临床HARMONi研究结果,PFS HR=0.52,OSHR=0.79,显示成功达到PFS主要终点,OS具有明显获益趋势。评论国际多中心临床HARMONi和中国临床HARMONi-A结果具备一致性。据康方和summit公告,HARMONi临床计划入组420 人,其中38%为欧美...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.